catapres-tts-1
Catapres-Tts-1 (Clonidine) is a central alpha-2 adrenergic agonist used to treat Attention Deficit Disorder with Hyperactivity, Diarrhea, Dysmenorrhea, Tourette Syndrome.
Clonidine · by Lavipharm
Every strength approved under this FDA application (3)
- Catapres-Tts-1 (this page)Clonidine 0.1MG/24HR
- Catapres-Tts-2Clonidine 0.2MG/24HR
- Catapres-Tts-3Clonidine 0.3MG/24HR
Key facts
- Active ingredient
- Clonidine
- Drug class
- Central Alpha-2 Adrenergic Agonist
- Form
- Patch
- Strength
- Clonidine 0.1MG/24HR
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- Manufacturer
- Lavipharm
- Half-life
- about 12 to 16 hours (how long it stays in your system)
- What the pharmacy pays
- ~$1.05 for 30 — not your price
- FDA application
- NDA018891
What is Catapres-Tts-1?
From the FDA label:Clonidine Transdermal System, USP provides continuous systemic delivery of clonidine for 7 days at an approximately constant rate. Clonidine is a centrally acting alpha‑agonist hypotensive agent. It is an imidazoline derivative with the chemical name 2,6‑dichloro‑N‑2‑imidazolidinylidenebenzenamine and has the following chemical structure: System Structure and Components Clonidine Transdermal System, USP is a multi-layered film, 0.2 mm thick, containing clonidine as the active agent. The system areas are 3.5 cm 2 (Clonidine Transdermal System USP, 0.1 mg/day), 7.0 cm 2 (Clonidine Transdermal System USP, 0.2 mg/day) and 10.5 cm 2 (Clonidine Transdermal System USP, 0.3 mg/day) and the amount of drug released is directly proportional to the area (see Release Rate Concept ). The composition per unit area is the same for all three doses. Proceeding from the visible surface towards the surface attached to the skin, there are four consecutive layers: 1) a backing layer of pigmented polyester and aluminum film; 2) a drug reservoir of clonidine, mineral oil, polyisobutylene, and colloidal silicon dioxide; 3) a microporous polypropylene membrane that controls the rate of delivery of clonidine from the system to the skin surface; 4) an adhesive formulation of clonidine, mineral oil, polyisobutylene, and colloidal silicon dioxide. Prior to use, a protective slit release liner of polyester…
How to use
Apply Clonidine Transdermal System, USP once every 7 days to a hairless area of intact skin on the upper outer arm or chest. Each new application of Clonidine Transdermal System, USP should be on a different skin site from the previous location. If the system loosens during 7‑day wearing, the adhesive cover should be applied directly over the system to ensure good adhesion. There have been rare reports of the need for patch changes prior to 7 days to maintain blood pressure control. To initiate therapy, Clonidine Transdermal System, USP dosage should be titrated according to individual therapeutic requirements, starting with Clonidine Transdermal System USP, 0.1 mg/day. If after one or two weeks the desired reduction in blood pressure is not achieved, increase the dosage by adding another Clonidine Transdermal System USP, 0.1 mg/day or changing to a larger system. An increase in dosage above two Clonidine Transdermal Systems USP, 0.3 mg/day is usually not associated with additional efficacy. When substituting Clonidine Transdermal System, USP for oral clonidine or for other antihypertensive drugs, physicians should be aware that the antihypertensive effect of Clonidine Transdermal System, USP may not commence until 2‑3 days after initial application. Therefore, gradual reduction of prior drug dosage is advised. Some or all previous antihypertensive treatment may have to be…
Side effects
Clinical trial experience with clonidine transdermal system Most systemic adverse effects during clonidine transdermal system therapy have been mild and have tended to diminish with continued therapy. In a 3‑month multi-clinic trial of clonidine transdermal system in 101 hypertensive patients, the systemic adverse reactions were, dry mouth (25 patients) and drowsiness (12), fatigue (6), headache (5), lethargy and sedation (3 each), insomnia, dizziness, impotence/sexual dysfunction, dry throat (2 each) and constipation, nausea, change in taste and nervousness (1 each). In the above mentioned 3‑month controlled clinical trial, as well as other uncontrolled clinical trials, the most frequent adverse reactions were dermatological and are described below. In the 3‑month trial, 51 of the 101 patients had localized skin reactions such as erythema (26 patients) and/or pruritus, particularly after using an adhesive cover throughout the 7‑day dosage interval. Allergic contact sensitization to clonidine transdermal system was observed in 5 patients. Other skin reactions were localized vesiculation (7 patients), hyperpigmentation (5), edema (3), excoriation (3), burning (3), papules (1), throbbing (1), blanching (1), and a generalized macular rash (1). In additional clinical experience, contact dermatitis resulting in treatment discontinuation was observed in 128 of 673 patients (about 19…
Warnings
Important safety information
Withdrawal Patients should be instructed not to discontinue therapy without consulting their physician. Sudden cessation of clonidine treatment has, in some cases, resulted in symptoms such as nervousness, agitation, headache, tremor, and confusion accompanied or followed by a rapid rise in blood pressure and elevated catecholamine concentrations in the plasma. The likelihood of such reactions to discontinuation of clonidine therapy appears to be greater after administration of higher doses or continuation of concomitant beta‑blocker treatment and special caution is therefore advised in these situations. Rare instances of hypertensive encephalopathy, cerebrovascular accidents and death have been reported after clonidine withdrawal. When discontinuing therapy with clonidine transdermal system, the physician should reduce the dose gradually over 2 to 4 days to avoid withdrawal symptomatology. An excessive rise in blood pressure following discontinuation of clonidine transdermal system therapy can be reversed by administration of oral clonidine hydrochloride or by intravenous phentolamine. If therapy is to be discontinued in patients receiving a beta‑blocker and clonidine concurrently, the beta‑blocker should be withdrawn several days before the gradual discontinuation of clonidine transdermal system.
Who should not take Catapres-Tts-1
Clonidine transdermal system should not be used in patients with known hypersensitivity to clonidine or to any other component of the transdermal system.
Overdose — what happens if you take too much
Hypertension may develop early and may be followed by hypotension, bradycardia, respiratory depression, hypothermia, drowsiness, decreased or absent reflexes, weakness, irritability and miosis. The frequency of CNS depression may be higher in children than adults. Large overdoses may result in reversible cardiac conduction defects or dysrhythmias, apnea, coma and seizures. Signs and symptoms of overdose generally occur within 30 minutes to two hours after exposure. As little as 0.1 mg of clonidine has produced signs of toxicity in children. If symptoms of poisoning occur following dermal exposure, remove all clonidine transdermal systems. After their removal, the plasma clonidine levels will persist for about 8 hours, then decline slowly over a period of several days. Rare cases of clonidine transdermal system poisoning due to accidental or deliberate mouthing or ingestion of the patch have been reported, many of them involving children. There is no specific antidote for clonidine overdosage. Ipecac syrup‑induced vomiting and gastric lavage would not be expected to remove significant amounts of clonidine following dermal exposure. If the patch is ingested, whole bowel irrigation may be considered and the administration of activated charcoal and/or cathartic may be beneficial. Supportive care may include atropine sulfate for bradycardia, intravenous fluids and/or vasopressor…
U.S. Poison Control: call or text 1-800-222-1222 (free, 24/7). In an emergency call 911. From the FDA label; not medical advice.
Interactions
Clonidine may potentiate the CNS-depressive effects of alcohol, barbiturates or other sedating drugs. If a patient receiving clonidine is also taking tricyclic antidepressants, the hypotensive effect of clonidine may be reduced, necessitating an increase in the clonidine dose. If a patient receiving clonidine is also taking neuroleptics, orthostatic regulation disturbances (e.g., orthostatic hypotension, dizziness, fatigue) may be induced or exacerbated. Monitor heart rate in patients receiving clonidine concomitantly with agents known to affect sinus node function or AV nodal conduction e.g., digitalis, calcium channel blockers, and beta‑blockers. Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concomitantly with diltiazem or verapamil. Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats (see Toxicology ).
How long does Clonidine stay in your body?
The elimination half-life of clonidine is about 12 to 16 hours — the time it takes the body to clear about half of it. As a rule of thumb, a medicine is mostly gone after roughly 4 to 5 half-lives, though this varies from person to person with age and kidney or liver function. The half-life gets much longer when the kidneys are not working well — up to about 41 hours in people with severe kidney impairment.
This is general information, not medical advice. It doesn’t tell you when a drug test would read negative (tests detect substances for different, often longer, windows) or when it’s safe to take another dose — ask your pharmacist or prescriber. Source: Clonidine Hydrochloride Tablets, USP (DailyMed).
Drug class
How this class works, per Clonidine - StatPearls - NCBI Bookshelf.
May treat (source: NIH RxClass)
- attention deficit disorder with hyperactivity
- diarrhea
- dysmenorrhea
- tourette syndrome
- glaucoma
- hypertension
See how Catapres-Tts-1 ranks — best-rated central alpha-2 adrenergic agonist for:
Dosage forms
Patch
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Catapres-Tts-1 treat?
- Catapres-Tts-1 (Clonidine) may be used to treat attention deficit disorder with hyperactivity, diarrhea, dysmenorrhea, tourette syndrome, glaucoma, hypertension, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- How does Catapres-Tts-1 work?
- Catapres-Tts-1 is a central alpha-2 adrenergic agonist. These drugs activate alpha-2 receptors in the brainstem, which tells the nervous system to send out less norepinephrine and reduce sympathetic (fight-or-flight) signaling to the body. With less of this stimulation, blood vessels relax and heart rate slows, lowering blood pressure.
- How much does Catapres-Tts-1 cost?
- Nobody can tell you what you will pay — your price is set by your insurer's formulary, your deductible and the pharmacy's markup, and none of those are published. What IS published is what the pharmacy paid to acquire it: about $1.05 for 30, per the CMS NADAC survey. Treat that as the floor, not the quote — ask the pharmacist for the cash price as well as your copay, because for cheap generics the cash price often wins.
- Is there a coupon or discount for Catapres-Tts-1?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Catapres-Tts-1. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Catapres-Tts-1?
- Catapres-Tts-1 is marketed by Lavipharm. You can see Lavipharm's full profile, rating, and other products on pharmaranks.
- Is Catapres-Tts-1 a brand-name or generic drug?
- Catapres-Tts-1 is a brand-name product with the active ingredient Clonidine.
- Is Catapres-Tts-1 available over the counter?
- No. Catapres-Tts-1 is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Catapres-Tts-1 come in?
- Catapres-Tts-1 is currently marketed as patch, per the FDA's National Drug Code Directory.
- What class of drug is Catapres-Tts-1?
- Catapres-Tts-1 is classified as central alpha-2 adrenergic agonist, per the FDA's Established Pharmacologic Class.
- Is Catapres-Tts-1 FDA-registered?
- Catapres-Tts-1 is on record with the U.S. FDA under application number NDA018891. You can verify this on its official FDA label.
- Is Catapres-Tts-1 safe?
- There's no single safe-or-not verdict, and we don't yet have a composite recall-safety score for Catapres-Tts-1. Review its FDA-label side effects and warnings below, and always consult a licensed professional.
- What are the side effects of Catapres-Tts-1?
- Catapres-Tts-1's side effects are taken directly from its FDA label. From the label: Clinical trial experience with clonidine transdermal system Most systemic adverse effects during clonidine transdermal system therapy have been mild and have tended to diminish with continued therapy. In a 3‑month multi-clinic trial of clonidine transdermal system in 101 hypertensive patients,… Both common and serious reactions are documented in full on this page. This is general reference from the FDA, not medical advice — always consult a professional.
Clinical content sourced from the FDA label via openFDA (U.S. FDA). View the FDA label on DailyMed → Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
Reviews
No reviews yet. Be the first to write one.
People also viewed
clonidine hydrochloride
Clonidine Hydrochloride
dexmedetomidine hydrochloride
Dexmedetomidine Hydrochloride
guanfacine hydrochloride
Guanfacine Hydrochloride
onyda xr
Clonidine Hydrochloride
javadin
Clonidine Hydrochloride
duraclon
Clonidine Hydrochloride
Compare Catapres-Tts-1 head-to-head
More central alpha-2 adrenergic agonist drugs
Guides for this medication
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
catapres-tts-1
New